이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Efficacy of High-Flow Humidified Oxygen (HFHO) in Apneic Oxygenation for Apnea Testing: A Comparison With Continuous Positive Airway Pressure (CPAP) (APNEAFLO2W)

2026년 7월 8일 업데이트: Centre Hospitalier Régional d'Orléans

Efficacy of High-Flow Humidified Oxygen in Apneic Oxygenation During Apnea Testing Compared With Continuous Positive Airway Pressure: A Randomized Multicenter Crossover Trial

Brain death (BD) is characterized by a severe brain injury resulting in irreversible loss of all brain and brainstem functions, while other organs may remain viable. The diagnosis of BD is based on the presence of coma, absence of brainstem reflexes, and absence of spontaneous breathing confirmed by an apnea test. In France, the apnea test is mandatory prior to organ procurement. The apnea test aims to demonstrate that hypercapnia, a strong ventilatory stimulus, does not induce any respiratory movements.

In current practice, the apnea test is performed by disconnecting the patient from mechanical ventilation for 8-10 minutes while administering oxygen. Oxygenation strategies during apnea vary across French centers. Although the use of continuous positive airway pressure (CPAP) is recommended, a substantial proportion of tests are still performed without positive end-expiratory pressure (PEEP) effect, using either an open T-piece or an intratracheal oxygen catheter. These methods are associated with a higher risk of complications, such as hypoxemia, and potential adverse effects on organ function, which is particularly relevant in the context of organ donation.

Humidified high-flow oxygen (HHFO), delivered via a specialized device connected to the endotracheal tube, provides high flow rates (up to 60 L/min), allows precise adjustment of the fraction of inspired oxygen (FiO₂ up to 1.0), and generates a minimal PEEP effect. HHFO is routinely used in intensive care units. While its feasibility during apnea testing has been reported, its efficacy during BD diagnosis has not been well evaluated.

Preliminary observations in intensive care patients with clinical brain death suggest that HHFO can be safely used during the apnea test, allowing achievement of hypercapnia and confirmation of absence of spontaneous respiration while maintaining better oxygenation compared with conventional oxygen delivery via an open T-piece.

This study aims to evaluate the efficacy of HHFO for apneic oxygenation during the apnea test, in comparison with the recommended method using CPAP.

연구 개요

상세 설명

The study strategy is based on performing two consecutive apnea tests in patients with clinical brain death, conducted in a randomized order. Only patients in whom the first apnea test confirms the absence of spontaneous breathing will proceed to the second apnea test. Consistency of clinical brain death at the end of the first apnea test are defined by the absence of any respiratory movement and the presence of either an arterial partial pressure of carbon dioxide (PaCO₂) ≥ 60 mmHg or an increase in PaCO₂ > 20 mmHg compared with the PaCO₂ measured at the end of the preoxygenation period.

Each of the two apnea tests will be preceded by a standardized 15-minute preoxygenation period using assisted controlled ventilation with a tidal volume of 6mL/kg of predicted body weight.

The two consecutive apnea tests will be performed in randomized order under CPAP and under HHFO with standardized parameters.

As per routine clinical practice, an arterial blood gas sample will be obtained before disconnection from the ventilator at the end of the preoxygenation period to confirm normocapnia, defined as 35 mmHg ≤ PaCO₂ ≤ 45 mmHg. A second arterial blood gas sample will be obtained at the end of the apnea test, prior to reconnection to the ventilator, to measure PaCO₂ and arterial partial pressure of oxygen (PaO₂).

Specifically for the purposes of the study, during each apnea test, the investigator will perform arterial blood gas sampling every 2 minutes to measure PaO₂, PaCO₂, and pH. At the same time points, arterial blood pressure, heart rate, pulse oximetry, and catecholamine infusion doses will be recorded.

In addition to these measurements required to meet the study objectives, demographic and clinical data will be collected primarily from the medical records to characterize the study population.

연구 유형

중재적

등록 (추정된)

28

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Adult intensive care unit patients
  • fulfilling all criteria for clinical brain death, for whom confirmation of the absence of spontaneous breathing requires performance of an apnea test
  • And for whom consent to participate in the study was sought from a trusted person or a family member

Exclusion Criteria:

  • History of chronic obstructive pulmonary disease (COPD) classified as GOLD stage III or IV.
  • Current extracorporeal life support, including veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO).
  • PaO₂/FiO₂ ratio ≤ 150 on the most recent arterial blood gas analysis, obtained within 24 hours prior to the screening visit.
  • Presence of at least one clear or absolute contraindication to the procurement of at least one organ.
  • Presence of a high cervical spinal cord injury.
  • Patient in the prone position and/or with a contraindication to placement in the supine position at 30°.
  • Minor patient.
  • Protected adult under legal guardianship or curatorship.
  • Individual under judicial protection (safeguard of justice).
  • Individuals deprived of liberty.
  • Individual not covered by a social security or health insurance system.
  • Pregnant or breastfeeding woman.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm HHFO in first
HHFO in first: in this arm, the first of the two consecutive apnea tests is performed under HHFO, followed by a second apnea test under CPAP.
For each 10-minute apnea test, regardless of the oxygenation device used, arterial blood gas will be analysed and heart rate, arterial pressure, and pulse oximetry will be recorded in 2-minute intervals.
For each 10-minute apnea test, regardless of the oxygenation device used, arterial blood gas will be analysed and heart rate, arterial pressure, and pulse oximetry will be recorded in 2-minute intervals.
실험적: Arm CPAP in first.
CPAP in first: in this arm, the first of the two consecutive apnea tests is performed under CPAP, followed by a second apnea test under HHFO.
For each 10-minute apnea test, regardless of the oxygenation device used, arterial blood gas will be analysed and heart rate, arterial pressure, and pulse oximetry will be recorded in 2-minute intervals.
For each 10-minute apnea test, regardless of the oxygenation device used, arterial blood gas will be analysed and heart rate, arterial pressure, and pulse oximetry will be recorded in 2-minute intervals.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in PaO₂ (mmHg) between the beginning and the end of an apnea test under HHFO and CPAP
기간: From ventilator disconnection to 10th minute of the apnea test
To demonstrate the non-inferiority of humidified high-flow oxygen compared to continuous positive airway pressure in apneic oxygenation for apnea testing.
From ventilator disconnection to 10th minute of the apnea test

2차 결과 측정

결과 측정
측정값 설명
기간
Evolution of arterial blood PaO2 parameters during the apnea test under HHFO and the apnea test with CPAP
기간: At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Recording of PaO2 values measured in 2-minute intervals during the apnea test under HHFO and apnea test with CPAP
At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Evolution of arterial blood PaCO2 parameters during the apnea test under HHFO and the apnea test with CPAP
기간: At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Recording of PaCO2 values measured in 2-minute intervals during the apnea test under HHFO and apnea test with CPAP
At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Evolution of arterial blood pH parameters during the apnea test under HHFO and the apnea test with CPAP
기간: At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Recording of pH values measured in 2-minute intervals during the apnea test under HHFO and apnea test with CPAP
At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Evolution of arterial blood pressure during the apnea test under HHFO and the apnea test with CPAP
기간: At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Recording of arterial blood pressure measured in 2-minute intervals during the apnea test under HHFO and with CPAP.
At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Evolution of heart rate during the apnea test under HHFO and the apnea test with CPAP
기간: At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Recording of heart rate measured in 2-minute intervals during the apnea test under HHFO and with CPAP.
At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Evolution of pulse oximetry during the apnea test under HHFO and the apnea test with CPAP
기간: At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Recording of pulse oximetry measured in 2-minute intervals during the apnea test under HHFO and with CPAP.
At 2-minute intervals from ventilator disconnection to the 10th minute of each apnea test
Time required to reach the hypercapnia thresholds necessary to confirm brain death during an apnea test under HHFO and with CPAP
기간: From ventilator disconnection until the hypercapnia threshold is reached
Time required to exceed 60mmHg of PaCO2 or for which PaCO2 increases by more than 20mmHg compared to the PaCO2 before disconnection during an apnea test under HHFO and with CPAP
From ventilator disconnection until the hypercapnia threshold is reached
Occurrence of apnea test interruptions during HHFO and CPAP.
기간: From ventilator disconnection until apnea test termination due to intolerance
Documentation of apnea test interruptions under HHFO and CPAP.
From ventilator disconnection until apnea test termination due to intolerance
Nurse-rated numeric scale evaluations of Humidified High Flow Oxygen and Continuous Positive Airway Pressure use for each enrolled patient
기간: Within 1 hour after each apnea test.
Nurse-rated ease of use will be assessed using a 4-point numeric scale (range: 0-3). The minimum score is 0 and the maximum score is 3. A score of 0 corresponds to very difficult use, and a score of 3 corresponds to very easy use. Higher scores indicate greater ease of use
Within 1 hour after each apnea test.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 15일

기본 완료 (추정된)

2028년 9월 15일

연구 완료 (추정된)

2028년 9월 15일

연구 등록 날짜

최초 제출

2026년 6월 5일

QC 기준을 충족하는 최초 제출

2026년 6월 5일

처음 게시됨 (실제)

2026년 6월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 8일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다